| Overview |
| bsm-70137M |
| Ki-67 Antibody |
| WB, IHC, ICC |
| Specific for endogenous levels of the ~345 & 395 kDa Ki-67 isoforms. Additional bands are thought to be breakdown products of these 2 isoforms. |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Recombinant construct containing the N-terminal 300 amino acids of the human sequence expressed in and purified from E. coli. |
| Monoclonal |
| 6G3 |
| IgG1 |
| Lot Dependent |
| Purified by Protein G. |
| PBS + 50% glycerol and 5 mm NaN3 |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| 4288 |
| P46013 |
| Antigen identified by monoclonal antibody Ki 67 antibody, Antigen identified by monoclonal antibody Ki-67 antibody, Antigen KI-67 antibody, Antigen KI67 antibody, Antigen Ki67 antibody, Ki67 antibody, KI67_HUMAN antibody, KIA antibody, Marker of proliferation Ki-67 antibody, MIB 1 antibody, MIB antibody, MKI67 antibody, PPP1R105 antibody, Proliferation marker protein Ki-67 antibody, Proliferation related Ki 67 antigen antibody, Protein phosphatase 1 regulatory subunit 105 antibody, RP11-380J17.2 antibody |
| Ki-67 is a nuclear protein that is considered to be essential for cellular proliferation since it is expressed only in active phases of the cell cycle (G1, S, G2 and mitosis) but not in resting phase G0 (Scholzen & Gerdes 2000). Ki-67 antibodies have therefore been widely used as markers of cell growth. Ki-67 has further been identified as a predicative and prognostic marker in breast, lung, cervical and other cancers (Yerushalmi et al., 2010; Folescu et al., 2018; Das et al., 2018). |
| Application Dilution |
| WB |
1:300-5000 |
| IHC |
|
| ICC |
1:100-500 |
Powered by Bioz